Abstract
The prognosis of metastatic non-small cell lung cancer (NSCLC) is poor, and platinum-based chemotherapy improves the median survival for only a few months. A subgroup of patients with oligometastatic disease may benefit from surgical resection, but only very limited data are available to date. We conducted a retrospective review of all patients with synchronous extrapulmonary oligometastatic NSCLC undergoing surgical resection in our department. Data regarding medical history, histology, number of metastases, and survival status were extracted from the medical database of the University Medical Center, Freiburg. Fifty-six patients underwent surgical resection for oligometastatic lung cancer. Five patients were lost during follow-up and therefore censored. One patient died perioperatively due to acute respiratory distress syndrome. The remaining 50 patients had an overall median survival time of 14.6 months. Analyzing the influence of metastatic site, we found a median overall survival of 23.4 months for patients with soft tissue metastasis, 16.7 months for patients with brain metastasis, 9.5 months for patients with adrenal gland involvement, and only 4.3 months for patients with bone metastasis (p < 0.005). Upon multivariate analysis, bone metastasis was the only significant parameter influencing median overall survival (p < 0.004). Based on our data, we conclude that an aggressive surgical approach for oligometastatic NSCLC can be performed with acceptable mortality and morbidity. In this rare constellation, surgical therapy may be an option in selected cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Underwood JM, Townsend JS, Tai E et al (2012) Racial and regional disparities in lung cancer incidence. Cancer 118:1910–1918. doi:10.1002/cncr.26479
Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59:828–836. doi:10.1136/thx.2003.020164
Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266. doi:10.1200/JCO.2009.23.5622
Group N-SCLCC (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909
Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol 9:1618–1626
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
Bonnette P, Puyo P, Gabriel C et al (2001) Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 119:1469–1475
Luketich JD, Burt ME (1996) Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg 62:1614–1616
Luketich JD, Martini N, Ginsberg RJ et al (1995) Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thorac Surg 60:1609–1611. doi:10.1016/0003-4975(95)00760-1
Wronski M, Arbit E, Burt M et al (1995) Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 83:605–616. doi:10.3171/jns.1995.83.4.0605
Salah S, Tanvetyanon T, Abbasi S (2011) Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. doi:10.1016/j.lungcan.2011.07.014
Hasselle MD, Haraf DJ, Rusthoven KE et al (2012) Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 7:376–381. doi:10.1097/JTO.0b013e31824166a5
Groome PA, Bolejack V, Crowley JJ et al (2007) The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:694–705. doi:10.1097/JTO.0b013e31812d05d5
Travis WD TVC, Corrin B (1999) Histological typing of lung and pleural tumours (International Histological Classification of Tumours). Springer, Berlin
Pfannschmidt J, Dienemann H (2010) Surgical treatment of oligometastatic non-small cell lung cancer. Lung Cancer 69:251–258. doi:10.1016/j.lungcan.2010.05.003
Dai L, Fang J, Nie J et al (2010) Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months. Zhongguo Fei Ai Za Zhi 13:1050–1055. doi:10.3779/j.issn.1009-3419.2010.11.10
Hoang T, Xu R, Schiller JH et al (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23:175–183. doi:10.1200/JCO.2005.04.177
Raynaud CM, Mercier O, Dartevelle P et al (2010) Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. Clin Lung Cancer 11:187–191. doi:10.3816/CLC.2010.n.024
Acknowledgments
We would like to thank Lydia Faricelli for the excellent assistance and proofreading of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Plönes, T., Osei-Agyemang, T., Krohn, A. et al. Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer. Indian J Surg 77 (Suppl 2), 216–220 (2015). https://doi.org/10.1007/s12262-012-0771-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-012-0771-6